A median OS of 12 months was observed in patients with KRAS+/TP53+ mutant cancer who had received treatment in a phase I clinical trial, consistent with a previous study showing a median OS of 10 months in 1,181 consecutive cancer patients treated in phase I clinical trials [23]. Here, KRAS is linked to cancer.